Neuraminidase Inhibitor Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1064407
  • May 2021
  • Pharmaceuticals
  • 135 Pages
The Neuraminidase Inhibitor market research report provides an in-depth analysis of the currents trends, latest developments, scenario, market size, various drivers, restraints, and major players along with their profile details. Research report offers the historic data for year 2018 and 2019 and also provides the forecast data from year 2020 to 2028 which is based on revenue (USD Million). With the help of all these information research report helps the market participants to improve market positions. With the help of all these insights Neuraminidase Inhibitor market research report recommends a business strategy for present market participants to strengthen their position in the market.
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered Strides Consumer LLC, BioCryst Pharmaceuticals, Inc, Teva Pharmaceuticals Industries Ltd, NATCO Pharma Limited, Alvogen, Amneal Pharmaceuticals LLC, Macleods Pharmaceuticals Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Lupin
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Impact Analysis
The analysis of covid-19 is based on the impact of the current pandemic situation on market scenarios. This includes impact of covid-19 outbreak on overall revenue, market segments as well as regional market. The report also puts light on detailed impact analysis by taking into consideration all the government policies imposed during the pandemic situation, temporary shutdown of manufacturing units, current state of supply chain and distributors, and its future impacts on the growth of overall market. The market study will assist user to understand the global demand and impose strategic business plans to compete with the peers.

Furthermore, the research report includes the detailed information about major players and provides the data regarding the current market scenario as well as upcoming market opportunities or challenges. Similarly, in segment report covers the types, and applications according to the countries and key regions. The research report consists the various drivers and restraints for Neuraminidase Inhibitor market along with their effects over the forecast period. Similarly, according to the region Neuraminidase Inhibitor market research report includes the study of opportunities available in the market situation.

The Neuraminidase Inhibitor market research report provides the in-depth data analysis by using the various graphs, figures, charts, and tables. Furthermore, the report provides the different business challenges which are impacting market growth in all direction.

Major Key Players for Global Neuraminidase Inhibitor Market:
The Neuraminidase Inhibitor market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Strides Consumer LLC, BioCryst Pharmaceuticals, Inc, Teva Pharmaceuticals Industries Ltd, NATCO Pharma Limited, Alvogen, Amneal Pharmaceuticals LLC, Macleods Pharmaceuticals Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Lupin

Neuraminidase Inhibitor Market Segmentation Analysis:
By Indication
Influenza Virus A
Influenza Virus B
Others
Drug Type
Zanamivir
Oseltamivir
Peramivir
Laninamivir
Other
Route of Administration
Parenteral
Oral
Others
Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Others

Global Neuraminidase Inhibitor Market Segmentation by Regions:
In regional analysis, Neuraminidase Inhibitor market research report provides the detailed analysis from various regions and also contains the detailed analysis of country. Along with market revenue, market value report also offers the forecast analysis for the following countries and regions. Global Neuraminidase Inhibitor market report covers the various geographical regions such as North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Also, various countries included are Canada, U.K., France, the U.S., Japan, China, India, and Germany and so on.

North America Region for Neuraminidase Inhibitor Market: Value and Forecast
  • U.S.
  • Canada
 Europe Region for Neuraminidase Inhibitor Market: Value and Forecast
  • UK
  • Germany
  • France
  • Rest of the Europe
 Asia Pacific Region for Neuraminidase Inhibitor Market: Value and Forecast
  • China
  • Japan
  • India
  • Rest of the Asia Pacific
 Latin America Region for Neuraminidase Inhibitor Market: Value and Forecast
  • Mexico
  • Brazil
  • Rest of the Latin America
 Middle East and Africa for Neuraminidase Inhibitor Market: Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa


Important Points Covered by Report:
  • To analyze the value of the Neuraminidase Inhibitor market, according to the key region.
  • To study the Neuraminidase Inhibitor market current trends, prospects and also their participation in the entire sector.
  • Report consists the in-depth information related to the region/countries, major key players, current trends and their analysis, product type, applications, and other background information
  • Report provides the detailed information about drivers, restraints and future scope of Neuraminidase Inhibitor market.
  • Report covers the information about historic data analysis as well as forecast period analysis.

Global Neuraminidase Inhibitor research report consist the information about overall sales and revenue during the historic and forecasted period of 2018 to 2028. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Neuraminidase Inhibitor market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Neuraminidase Inhibitor market for numerous purposes such as:

    1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Neuraminidase Inhibitor market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Neuraminidase Inhibitor market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Neuraminidase Inhibitor market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • Strides Consumer LLC
  • BioCryst Pharmaceuticals, Inc
  • Teva Pharmaceuticals Industries Ltd
  • NATCO Pharma Limited
  • Alvogen
  • Amneal Pharmaceuticals LLC
  • Macleods Pharmaceuticals Ltd
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Lupin
  • Influenza Virus A
  • Influenza Virus B
  • Others
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Neuraminidase Inhibitor Market Snapshot
          2.1.1. Global Neuraminidase Inhibitor Market By Indication,2019
               2.1.1.1.Influenza Virus A
               2.1.1.2.Influenza Virus B
               2.1.1.3.Others
          2.1.2. Global Neuraminidase Inhibitor Market By Distribution Channel,2019
               2.1.2.1.Hospital Pharmacy
               2.1.2.2.Retail Pharmacy
               2.1.2.3.Others
          2.1.3. Global Neuraminidase Inhibitor Market By End-use,2019
          2.1.4. Global Neuraminidase Inhibitor Market By Geography,2019

3. Global Neuraminidase Inhibitor Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Neuraminidase Inhibitor Market Size (US$), By Indication, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Indication, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Indication, 2020
     4.2. Global Neuraminidase Inhibitor Market Size (US$), By Indication, 2018 – 2028

5. Global Neuraminidase Inhibitor Market Size (US$), By Distribution Channel, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Distribution Channel, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Distribution Channel, 2020
     5.2. Global Neuraminidase Inhibitor Market Size (US$), By Distribution Channel, 2018 – 2028

6. Global Neuraminidase Inhibitor Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Neuraminidase Inhibitor Market Size (US$), By End-use, 2018 – 2028

7. Global Neuraminidase Inhibitor Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Neuraminidase Inhibitor Market Analysis, 2018 – 2028 
          7.2.1. North America Neuraminidase Inhibitor Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Neuraminidase Inhibitor Market Size (US$), By Indication, 2018 – 2028
          7.2.3. North America Neuraminidase Inhibitor Market Size (US$), By Distribution Channel, 2018 – 2028
          7.2.4. North America Neuraminidase Inhibitor Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Neuraminidase Inhibitor Market Analysis, 2018 – 2028 
          7.3.1.  Europe Neuraminidase Inhibitor Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Neuraminidase Inhibitor Market Size (US$), By Indication, 2018 – 2028
          7.3.3. Europe Neuraminidase Inhibitor Market Size (US$), By Distribution Channel, 2018 – 2028
          7.3.4. Europe Neuraminidase Inhibitor Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Neuraminidase Inhibitor Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Neuraminidase Inhibitor Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Neuraminidase Inhibitor Market Size (US$), By Indication, 2018 – 2028
          7.4.3. Asia Pacific Neuraminidase Inhibitor Market Size (US$), By Distribution Channel, 2018 – 2028
          7.4.4. Asia Pacific Neuraminidase Inhibitor Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Neuraminidase Inhibitor Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Neuraminidase Inhibitor Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Neuraminidase Inhibitor Market Size (US$), By Indication, 2018 – 2028
          7.5.3. Latin America Neuraminidase Inhibitor Market Size (US$), By Distribution Channel, 2018 – 2028
          7.5.4. Latin America Neuraminidase Inhibitor Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Neuraminidase Inhibitor Market Analysis, 2018 – 2028 
          7.6.1.  MEA Neuraminidase Inhibitor Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Neuraminidase Inhibitor Market Size (US$), By Indication, 2018 – 2028
          7.6.3. MEA Neuraminidase Inhibitor Market Size (US$), By Distribution Channel, 2018 – 2028
          7.6.4. MEA Neuraminidase Inhibitor Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Neuraminidase Inhibitor Providers
        8.4.1 Strides Consumer LLC
                8.4.1.1 Business Description
                8.4.1.2 Strides Consumer LLC Geographic Operations
                8.4.1.3 Strides Consumer LLC Financial Information
                8.4.1.4 Strides Consumer LLC Product Positions/Portfolio
                8.4.1.5 Strides Consumer LLC Key Developments
        8.4.2 BioCryst Pharmaceuticals, Inc
                8.4.2.1 Business Description
                8.4.2.2 BioCryst Pharmaceuticals, Inc Geographic Operations
                8.4.2.3 BioCryst Pharmaceuticals, Inc Financial Information
                8.4.2.4 BioCryst Pharmaceuticals, Inc Product Positions/Portfolio
                8.4.2.5 BioCryst Pharmaceuticals, Inc Key Developments
        8.4.3 Teva Pharmaceuticals Industries Ltd
                8.4.3.1 Business Description
                8.4.3.2 Teva Pharmaceuticals Industries Ltd Geographic Operations
                8.4.3.3 Teva Pharmaceuticals Industries Ltd Financial Information
                8.4.3.4 Teva Pharmaceuticals Industries Ltd Product Positions/Portfolio
                8.4.3.5 Teva Pharmaceuticals Industries Ltd Key Developments
        8.4.4 NATCO Pharma Limited
                8.4.4.1 Business Description
                8.4.4.2 NATCO Pharma Limited Geographic Operations
                8.4.4.3 NATCO Pharma Limited Financial Information
                8.4.4.4 NATCO Pharma Limited Product Positions/Portfolio
                8.4.4.5 NATCO Pharma Limited Key Developments
        8.4.5 Alvogen
                8.4.5.1 Business Description
                8.4.5.2 Alvogen Geographic Operations
                8.4.5.3 Alvogen Financial Information
                8.4.5.4 Alvogen Product Positions/Portfolio
                8.4.5.5 Alvogen Key Developments
        8.4.6 Amneal Pharmaceuticals LLC
                8.4.6.1 Business Description
                8.4.6.2 Amneal Pharmaceuticals LLC Geographic Operations
                8.4.6.3 Amneal Pharmaceuticals LLC Financial Information
                8.4.6.4 Amneal Pharmaceuticals LLC Product Positions/Portfolio
                8.4.6.5 Amneal Pharmaceuticals LLC Key Developments
        8.4.7 Macleods Pharmaceuticals Ltd
                8.4.7.1 Business Description
                8.4.7.2 Macleods Pharmaceuticals Ltd Geographic Operations
                8.4.7.3 Macleods Pharmaceuticals Ltd Financial Information
                8.4.7.4 Macleods Pharmaceuticals Ltd Product Positions/Portfolio
                8.4.7.5 Macleods Pharmaceuticals Ltd Key Developments
        8.4.8 F. Hoffmann-La Roche Ltd
                8.4.8.1 Business Description
                8.4.8.2 F. Hoffmann-La Roche Ltd Geographic Operations
                8.4.8.3 F. Hoffmann-La Roche Ltd Financial Information
                8.4.8.4 F. Hoffmann-La Roche Ltd Product Positions/Portfolio
                8.4.8.5 F. Hoffmann-La Roche Ltd Key Developments
        8.4.9 GlaxoSmithKline Plc
                8.4.9.1 Business Description
                8.4.9.2 GlaxoSmithKline Plc Geographic Operations
                8.4.9.3 GlaxoSmithKline Plc Financial Information
                8.4.9.4 GlaxoSmithKline Plc Product Positions/Portfolio
                8.4.9.5 GlaxoSmithKline Plc Key Developments
        8.4.10 Lupin
                8.4.10.1 Business Description
                8.4.10.2 Lupin Geographic Operations
                8.4.10.3 Lupin Financial Information
                8.4.10.4 Lupin Product Positions/Portfolio
                8.4.10.5 Lupin Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Neuraminidase Inhibitor Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Neuraminidase Inhibitor Market Revenue, By Indication, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Neuraminidase Inhibitor Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Neuraminidase Inhibitor Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Neuraminidase Inhibitor Market Revenue, By Indication, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Neuraminidase Inhibitor Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Neuraminidase Inhibitor Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Neuraminidase Inhibitor Market Revenue, By Indication, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Neuraminidase Inhibitor Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Neuraminidase Inhibitor Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Neuraminidase Inhibitor Market Revenue, By Indication, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Neuraminidase Inhibitor Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Neuraminidase Inhibitor Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Neuraminidase Inhibitor Market Revenue, By Indication, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Neuraminidase Inhibitor Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Neuraminidase Inhibitor Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Neuraminidase Inhibitor: Market Segmentation 
FIG. 2 Global Neuraminidase Inhibitor Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Neuraminidase Inhibitor Market, By Indication, 2019 (US$ Mn) 
FIG. 5 Global Neuraminidase Inhibitor Market, By Distribution Channel, 2019 (US$ Mn) 
FIG. 6 Global Neuraminidase Inhibitor Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Neuraminidase Inhibitor Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Neuraminidase Inhibitor Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Neuraminidase Inhibitor Providers, 2019
FIG. 11 Global Neuraminidase Inhibitor Market Revenue Contribution, By Indication, 2019 & 2028 (Value %) 
FIG. 12 Global Neuraminidase Inhibitor Market Revenue Contribution, By Distribution Channel, 2019 & 2028 (Value %) 
FIG. 13 Global Neuraminidase Inhibitor Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Neuraminidase Inhibitor Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Neuraminidase Inhibitor Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Neuraminidase Inhibitor Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Neuraminidase Inhibitor Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Neuraminidase Inhibitor Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Neuraminidase Inhibitor market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Neuraminidase Inhibitor Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Neuraminidase Inhibitor Market Value, By Segment1, 2018 – 2028
TABLE  North America Neuraminidase Inhibitor Market Value, By Segment2, 2018 – 2028
TABLE  North America Neuraminidase Inhibitor Market Value, By Country, 2018 – 2028
TABLE  Europe Neuraminidase Inhibitor Market Value, By Segment1, 2018 – 2028
TABLE  Europe Neuraminidase Inhibitor Market Value, By Segment2, 2018 – 2028
TABLE  Europe Neuraminidase Inhibitor Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Neuraminidase Inhibitor Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Neuraminidase Inhibitor Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Neuraminidase Inhibitor Market Value, By Country, 2018 – 2028
TABLE  Latin America Neuraminidase Inhibitor Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Neuraminidase Inhibitor Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Neuraminidase Inhibitor Market Value, By Country, 2018 – 2028
TABLE  MEA Neuraminidase Inhibitor Market Value, By Segment1, 2018 – 2028
TABLE  MEA Neuraminidase Inhibitor Market Value, By Segment2, 2018 – 2028
TABLE  MEA Neuraminidase Inhibitor Market Value, By Country, 2018 – 2028
TABLE  Strides Consumer LLC: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  BioCryst Pharmaceuticals, Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Teva Pharmaceuticals Industries Ltd: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  NATCO Pharma Limited: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Alvogen: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Amneal Pharmaceuticals LLC: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Macleods Pharmaceuticals Ltd: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  F. Hoffmann-La Roche Ltd: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GlaxoSmithKline Plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Lupin: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Neuraminidase Inhibitor Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Neuraminidase Inhibitor Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Neuraminidase Inhibitor Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Neuraminidase Inhibitor Market, By Geography, 2019 (US$ Mn)
FIG.  Global Neuraminidase Inhibitor Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Neuraminidase Inhibitor Providers, 2016
FIG.  Global Neuraminidase Inhibitor Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Influenza Virus B Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Neuraminidase Inhibitor Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Retail Pharmacy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Neuraminidase Inhibitor Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Neuraminidase Inhibitor Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Neuraminidase Inhibitor Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Neuraminidase Inhibitor Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Neuraminidase Inhibitor Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Neuraminidase Inhibitor Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Neuraminidase Inhibitor Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Neuraminidase Inhibitor Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Neuraminidase Inhibitor Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Neuraminidase Inhibitor Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Neuraminidase Inhibitor Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Neuraminidase Inhibitor Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Neuraminidase Inhibitor Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Neuraminidase Inhibitor Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Neuraminidase Inhibitor Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Neuraminidase Inhibitor Market Value, 2018 – 2028, (US$ Mn)